Organovo Holdings, Inc. (ONVO) financial statements (2022 and earlier)

Company profile

Business Address 11555 SORRENTO VALLEY ROAD
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End March 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q3
9/30/2021
Q2
6/30/2021
Q1
3/31/2021
Q4
12/31/2020
Q3
9/30/2020
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments30,26933,79136,008 18,83617,656
Cash and cash equivalents30,26933,79136,008 18,83617,656
Receivables     19
Other undisclosed current assets902512650 1,2631,810
Total current assets:31,17134,30336,658 20,09919,485
Noncurrent Assets
Operating lease, right-of-use asset2,269     
Property, plant and equipment652552554 28922
Restricted cash and investments143111111 111 
Other undisclosed noncurrent assets860915971 1,0821,137
Total noncurrent assets:3,9241,5781,636 1,4821,159
TOTAL ASSETS:35,09535,88138,294 21,58120,644
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,5311,675964 829658
Accounts payable605958577 411201
Accrued liabilities926717387 418457
Other undisclosed current liabilities475     
Total current liabilities:2,0061,675964 829658
Noncurrent Liabilities
Long-term debt and lease obligation1,796     
Operating lease, liability1,796     
Other undisclosed noncurrent liabilities(1,796)     
Total noncurrent liabilities:1,796     
Total liabilities:3,8021,675964 829658
Stockholders' equity
Stockholders' equity attributable to parent31,29334,20637,330 20,75219,986
Common stock999 77
Treasury stock, value(1)(1)(1) (1)(1)
Additional paid in capital337,113336,526336,145 314,441311,164
Accumulated deficit(305,828)(302,328)(298,823) (293,695)(291,184)
Total stockholders' equity:31,29334,20637,330 20,75219,986
TOTAL LIABILITIES AND EQUITY:35,09535,88138,294 21,58120,644

Income statement (P&L) ($ in thousands)

12/31/2021
Q3
9/30/2021
Q2
6/30/2021
Q1
3/31/2021
Q4
12/31/2020
Q3
9/30/2020
Q2
Operating expenses(3,500)(3,507)(2,559) (2,492)(8,950)
Operating loss:(3,500)(3,507)(2,559) (2,492)(8,950)
Nonoperating income (expense)2227 (19)5
Investment income, nonoperating222 14
Other nonoperating income  25  1
Loss from continuing operations before income taxes:(3,498)(3,505)(2,532) (2,511)(8,945)
Income tax expense(2)     
Loss before gain (loss) on sale of properties:(3,500)(3,505)(2,532) (2,511)(8,945)
Other undisclosed net loss     (5)
Net loss available to common stockholders, diluted:(3,500)(3,505)(2,532) (2,511)(8,950)

Comprehensive Income ($ in thousands)

12/31/2021
Q3
9/30/2021
Q2
6/30/2021
Q1
3/31/2021
Q4
12/31/2020
Q3
9/30/2020
Q2
Net loss:(3,500)(3,505)(2,532) (2,511)(8,950)
Comprehensive loss, net of tax, attributable to parent:(3,500)(3,505)(2,532) (2,511)(8,950)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: